Related Experiment Video
Updated: Feb 24, 2026
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
microRNA-133a attenuates cardiomyocyte hypertrophy by targeting PKCδ and Gq
Se-Yeon Lee1, Chang Youn Lee2, Onju Ham1
1Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Republic of Korea.
Abstract:
During the past decade, microRNAs have continuously been suggested as a promising therapeutic tool due to their beneficial effects, such as their multi-targets and multi-functions in pathologic conditions. As a pathologic phenotype is generally regulated by multiple signaling pathways, in this study we identified a microRNA regulating multiple target genes within cardiac hypertrophic signaling pathways. microRNA-133a is known to play a crucial role in cardiac hypertrophy. However, the role of microRNA-133a, which may regulate several signaling pathways in norepinephrine-induced cardiac hypertrophy via multi-targeting, has not been investigated. In the current study, we showed that microRNA-133a can protect cardiomyocyte hypertrophy against norepinephrine stimulation in neonatal rat ventricular cardiomyocytes via new targets, PKCδ and Gq, all of which are related to downstream signaling pathways of the α1-adrenergic receptor. Taken together, these results suggest the advantages of the therapeutic use of microRNAs as an effective potential drug regulating multiple signaling pathways under pathologic conditions.
Insights
MicroRNA-133a protects against cardiac hypertrophy by targeting multiple pathways, including PKCδ and Gq. This finding highlights microRNAs as potential therapeutic drugs for complex cardiac conditions.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Gene Regulation
Background:
- MicroRNAs are recognized for their therapeutic potential in diseases due to their multi-targeting capabilities.
- Cardiac hypertrophy is a complex condition often involving multiple signaling pathways.
- The specific role of microRNA-133a in regulating multiple pathways during norepinephrine-induced cardiac hypertrophy remains underexplored.
Purpose of the Study:
- To investigate the role of microRNA-133a in regulating multiple signaling pathways involved in cardiac hypertrophy.
- To identify novel targets of microRNA-133a in the context of norepinephrine-induced cardiac hypertrophy.
- To evaluate the protective effects of microRNA-133a against cardiac hypertrophy.
Main Methods:
- Neonatal rat ventricular cardiomyocytes were used to study cardiac hypertrophy.
- Norepinephrine was employed to induce cardiac hypertrophy.
- The expression and function of microRNA-133a, PKCδ, and Gq were analyzed in relation to α1-adrenergic receptor signaling.
Main Results:
- MicroRNA-133a demonstrated a protective effect against norepinephrine-induced cardiomyocyte hypertrophy.
- Novel targets, protein kinase C delta (PKCδ) and Gq, were identified as being regulated by microRNA-133a.
- These targets are implicated in downstream signaling pathways of the α1-adrenergic receptor.
Conclusions:
- MicroRNA-133a effectively mitigates cardiac hypertrophy by targeting multiple signaling molecules, including PKCδ and Gq.
- The multi-targeting nature of microRNA-133a offers therapeutic advantages for complex pathologies like cardiac hypertrophy.
- MicroRNAs represent a promising class of drugs for treating conditions involving dysregulated signaling pathways.
More Related Videos
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
